Arlington Trust’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Arlington Trust’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.6K	Hold	450	–	–	﹤0.01%	287
2026 Q1	$39K	Hold	450	–	–	﹤0.01%	252
2025 Q4	$38.2K	Hold	450	–	–	﹤0.01%	219
2025 Q3	$32.7K	Hold	450	–	–	0.01%	401
2025 Q2	$29.5K	Hold	450	–	–	0.01%	403
2025 Q1	$31.8K	Buy	+450	New	+$31.3K	0.01%	408

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Arlington Trust's IHE Position: Q2 2026 in Review

Arlington Trust held its iShares US Pharmaceuticals ETF (IHE) position steady in Q2 2026 at 450 shares worth $44.6K. The position accounts for ﹤0.01% of the portfolio, ranked #287.

Arlington Trust first reported a position in IHE in Q1 2025 and has held it in 6 quarters since. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Arlington Trust held 450 shares of iShares US Pharmaceuticals ETF worth $44.6K as of Q2 2026.
Arlington Trust left its iShares US Pharmaceuticals ETF share count unchanged in Q2 2026.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #287 holding.
Arlington Trust first reported a position in iShares US Pharmaceuticals ETF in Q1 2025 and has held it in 6 quarters since.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.